PT-141 (Libido/Sex drive) 10mg – Apoxar PT-141 (Libido/Sex drive) 10mg – Apoxar, also known as Bremelanotide, is a synthetic peptide used primarily for improving libido and treating sexual dysfunction in both men and women. It is sold under brand names like Vyleesi and is also available in research-grade forms like Apoxar PT-141 10mg. PT-141 works by targeting melanocortin receptors in the brain, which influence sexual arousal and desire. Mechanism of Action Melanocortin Receptor Agonist: PT-141 binds to MC3R and MC4R (melanocortin receptors) in the central nervous system, bypassing hormonal pathways to directly stimulate sexual arousal. Unlike PDE-5 inhibitors (e.g., Viagra), PT-141 does not act on blood flow but on the neurological pathways that trigger sexual desire. Key Benefits Improved Libido: Increases sexual arousal in both men and women. Effective for hypoactive sexual desire disorder (HSDD) in premenopausal women. Erectile Dysfunction (ED) Treatment: Helps men achieve and maintain erections, especially those with ED caused by psychological factors. Enhanced Sexual Pleasure: Many users report heightened sensitivity and overall sexual satisfaction. Alternative to PDE-5 Inhibitors: Ideal for individuals who cannot use drugs like Sildenafil (Viagra) or Tadalafil (Cialis). Dosage and Administration Standard Dosage: 1–2 mg subcutaneously (SC) injected about 30–60 minutes before sexual activity. Dosage can be adjusted based on individual tolerance and effectiveness, with a maximum of 2 mg per day. Reconstitution: If provided as a lyophilized powder (e.g., Apoxar PT-141 10mg), reconstitute with bacteriostatic water (typically 1–2 mL) and store in a refrigerator. Effects Timeline Onset: Effects are typically felt within 30–60 minutes of administration. Peak: Sexual arousal peaks around 2–4 hours after injection. Duration: Effects can last up to 8–12 hours, with residual benefits for up to 24 hours. Side Effects Common: Nausea (most reported side effect, dose-dependent). Flushing or warmth in the face. Mild headache. Temporary fatigue or dizziness. Less Common: Increased blood pressure (monitor in individuals with hypertension). Darkened skin pigmentation with prolonged use (related to melanocortin activity). Rare: Allergic reactions, including injection site irritation or swelling. Precautions Cardiovascular Conditions: Avoid use in individuals with uncontrolled high blood pressure or cardiovascular disorders, as PT-141 may cause mild increases in blood pressure. Pregnancy and Lactation: Not recommended for use during pregnancy or breastfeeding. Alcohol: Combining PT-141 with alcohol may increase dizziness and fatigue. Legal Status FDA Approval: PT-141 (Bremelanotide) is FDA-approved under the name Vyleesi for treating hypoactive sexual desire disorder (HSDD) in premenopausal women. Research Use: Research-grade PT-141 (like Apoxar 10mg) is sold for experimental purposes and may not meet pharmaceutical standards. Storage Before Reconstitution: Store the lyophilized powder in a cool, dry place away from sunlight. After Reconstitution: Store in the refrigerator (2–8°C) and use within 30–60 days, depending on the diluent used. Comparison to Other Sexual Function Enhancers PT-141 vs PDE-5 Inhibitors: PT-141 directly enhances libido and arousal, while PDE-5 inhibitors improve blood flow to the genitals. PT-141 is suitable for psychological or neurological sexual dysfunction, while PDE-5 inhibitors are better for physical causes like poor circulation. Sample Protocol (Example Use Case) Reconstitution: Mix 10 mg of PT-141 with 1 mL of bacteriostatic water to achieve 10 mg/mL concentration. Dosage: Inject 0.1–0.2 mL (1–2 mg) subcutaneously 30–60 minutes before activity. Cycle: Use as needed, no more than a few times weekly to avoid desensitization. It is sold under brand names like Vyleesi and is also available in research-grade forms like Apoxar PT-141 10mg. PT-141 works by targeting melanocortin receptors in the brain, which influence sexual arousal and desire. Mechanism of Action Melanocortin Receptor Agonist: PT-141 binds to MC3R and MC4R (melanocortin receptors) in the central nervous system, bypassing hormonal pathways to directly stimulate sexual arousal. Unlike PDE-5 inhibitors (e.g., Viagra), PT-141 does not act on blood flow but on the neurological pathways that trigger sexual desire. PT-141 (Libido/Sex drive) 10mg – Apoxar Key Benefits Improved Libido: Increases sexual arousal in both men and women. Effective for hypoactive sexual desire disorder (HSDD) in premenopausal women. Erectile Dysfunction (ED) Treatment: Helps men achieve and maintain erections, especially those with ED caused by psychological factors. Enhanced Sexual Pleasure: Many users report heightened sensitivity and overall sexual satisfaction. Alternative to PDE-5 Inhibitors: Ideal for individuals who cannot use drugs like Sildenafil (Viagra) or Tadalafil (Cialis). Dosage and Administration Standard Dosage: 1–2 mg subcutaneously (SC) injected about 30–60 minutes before sexual activity. Dosage can be adjusted based on individual tolerance and effectiveness, with a maximum of 2 mg per day. Reconstitution: If provided as a lyophilized powder (e.g., Apoxar PT-141 10mg), reconstitute with bacteriostatic water (typically 1–2 mL) and store in a refrigerator. Effects Timeline Onset: Effects are typically felt within 30–60 minutes of administration. Peak: Sexual arousal peaks around 2–4 hours after injection. Duration: Effects can last up to 8–12 hours, with residual benefits for up to 24 hours. Side Effects Common: Nausea (most reported side effect, dose-dependent). Flushing or warmth in the face. Mild headache. Temporary fatigue or dizziness. Less Common: Increased blood pressure (monitor in individuals with hypertension). Darkened skin pigmentation with prolonged use (related to melanocortin activity). Rare: Allergic reactions, including injection site irritation or swelling. Precautions Cardiovascular Conditions: Avoid use in individuals with uncontrolled high blood pressure or cardiovascular disorders, as PT-141 may cause mild increases in blood pressure. Pregnancy and Lactation: Not recommended for use during pregnancy or breastfeeding. Alcohol: Combining PT-141 with alcohol may increase dizziness and fatigue. Legal Status FDA Approval: PT-141 (Bremelanotide) is FDA-approved under the name Vyleesi for treating hypoactive sexual desire disorder (HSDD) in premenopausal women. Research Use: Research-grade PT-141 (like Apoxar 10mg) is sold for experimental purposes and may not meet pharmaceutical standards. Storage Before Reconstitution: Store the lyophilized powder in a cool, dry place away from sunlight. After Reconstitution: Store in the refrigerator (2–8°C) and use within 30–60 days, depending on the diluent used. Comparison to Other Sexual Function Enhancers PT-141 vs PDE-5 Inhibitors: PT-141 directly enhances libido and arousal, while PDE-5 inhibitors improve blood flow to the genitals. PT-141 is suitable for psychological or neurological sexual dysfunction, while PDE-5 inhibitors are better for physical causes like poor circulation. Sample Protocol (Example Use Case) Reconstitution: Mix 10 mg of PT-141 with 1 mL of bacteriostatic water to achieve 10 mg/mL concentration. Dosage: Inject 0.1–0.2 mL (1–2 mg) subcutaneously 30–60 minutes before activity. Cycle: Use as needed, no more than a few times weekly to avoid desensitization. PT-141 (Libido/Sex drive) 10mg – Apoxar
